HomePipelinePNB-101Liver Cancer

PNB-101

Liver Cancer

PNB-101 for the Treatment of Liver Cancer

Molecule
PNB-101
Development status
IND ready
Therapeutic area
Oncology
Biological action
CCK-B pathway inhibition
Therapeutic target
Cholecystokinin Receptors, CCK-B receptor blocker
Therapeutic indication
Liver Cancer
Same study also covers
Lung Cancer

Stage of development

  • PNB-101

    Liver CancerCCK-B pathway inhibition

Graph of the stage of development of PNB-101 in Liver Cancer. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.

The study below is the company document “PNB-101 for the Treatment of Lung/Liver and Gastric Cancers”, which covers Liver Cancer and Lung Cancer together.

Background about target:

Lung Cancer is the most (33.8/100.000) and fourth most (13.5/100.000) popular cancer in male and female, respectively. Lung Cancer is also the most popular cause of cancerous mortality, which accounted for 1.38 million deaths worldwide (18.2% in total) in 2008. The standard chemotherapy for late-stage non-small cell Lung Cancer is platinum-based (cisplatin, carboplatin, oxaliplatin) dual therapy (Pfister et al., 2004; Socinski et al., 2007). Based on a literature review, the CCK2 receptor is a validated molecular target for Lung Cancer. Moody published recently (Moody et al 2015; http://jpet.aspetjournals.org/content/299/3/1154.long) and the CCK2 antagonist CI-988 was an ideal candidate for the treatment of Lung Cancer. This is a final re-confirmation of his earlier work and also supports the link inflammation and cancer.

Preclinical studies:

The signaling pathway of CCK via the CCK 2/ gastrin receptors in cancer underpins the bioactivity found in vitro and in vivo. After stimulating CCK or gastrin, CCK-B/gastrin or CCK-C receptors will undergo a conformational change, which results in the isolation of Gα with two other Gβγ subunits of G-protein to interact with CCK receptor. Gα will then be activated and stimulates its downstream second messengers, which elicit various cellular processes relating to proliferation and survival of the cell. Initial results are in line with the literature. Using a C38 murine lung cell line, in vitro anti-cancer activity, was obtained better than CI-988.

In a xenograft study with the human transplanted Lung Cancer cell line NCI H727 more than 80% inhibition of tumour growth was obtained in nude mice after 28 days in responders by oral administration.

SAR optimisation was completed and inflammation was extended from the usual inflammation to neuro-inflammation for PNB-102 and from inflammation to cancer for PNB-101.

Preclinical development studies:

PNB-102 is the chlorinated sister molecule of PNB-101 and its higher lipophilicity is key in CNS applications.

The bioavailability of PNB-101 is enhanced by 700% compared to PNB-001 and the initial high concentration is required to mark the cancer area. Once marked, at lower concentrations, like PNB-001, PNB-101 will stimulate T cells proliferation, such as cytotoxic T cells, thus killing the previously marked cancerous cells.

Lung tissue and Liver Cancer tissue has the highest CCKB receptor expression enabling to mark best these cancers , but is not limited to a particular organ.

In vitro and in vivo anticancer the action was shown for lung and Gastric Cancer cell lines.

Synthetic chemistry:

PNB-101 synthetic scheme has only two steps and involve highly economical raw materials. PNB-102 is synthesized from chlorobenzene, which interestingly, is even cheaper than benzene and combined with mucochloric acid, which is available from furfural, it will be one of the cheapest API on the market. PNB-102 was successfully synthesized in good yields and high purity.

Ongoing studies:

Preclinical toxicology and safety pharmacology regulatory studies in accordance to ICH guidelines will be initiated after PNB-081.

Intellectual property:

PNB-101/2 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. A PCT application was also filed and granted. Examination by the PTO office in Washington DC did not find any infringement issues with this series of molecules. USPTO has issued the patent on December 28, 2014.

About PNB-101

IND ready

A targeted molecule for Gastrin-Related Cancers, with small cell lung, liver and Stomach Cancer as secondary indications. Lung and liver tissue show the highest CCK-B receptor expression.

PNB-101 full profile

Other indications of PNB-101

All molecules

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.